Referanser

Agustsson, T. T., Baldvinsdottir, T., Jonasson, J. G., Olafsdottir, E., Steinthorsdottir, V., Sigurdsson, G., Thorsson, A. V., Carroll, P. V., ... Benediktsson, R. (2015). The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. European Journal of Endocrinology of the European Federation of Endocrine Societies, 173(5), 655-64.

Ajithkumar, T., & Brada, M. (2004). Stereotactic linear accelerator radiotherapy for pituitary tumors. Treatments in Endocrinology, 3(4), 211-6.

Becker, G., Kocher, M., Kortmann, R. D., Paulsen, F., Jeremic, B., Müller, R. P., & Bamberg, M. (2002). Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 178(4), 173-86.

Bengtsson, D., Schrøder, H. D., Andersen, M., Maiter, D., Berinder, K., Feldt Rasmussen, U., Rasmussen Å, K., Johannsson, G., ... Burman, P. (2015). Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. Journal of Clinical Endocrinology and Metabolism, 100(4), 1689-98.

Brada, M., Burchell, L., Ashley, S., & Traish, D. (1999). The incidence of cerebrovascular accidents in patients with pituitary adenoma. International Journal of Radiation Oncology, Biology, Physics, 45(3), 693-8.

Brandal, P., Marienhagen, K., Nyström, P. W., Danielsen, T. (2023). Toleransedoser til risikoorganer ved strålebehandling av sentralnervesystemet (CNS) (Teknisk dokument nr. 29). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/inline/a5d17cc9-d8fa-4138-8ffc-c091eb2d122e:db1b583d5d4b878b3311ab387f73b96ab89ccc3a/Teknisk%20dokument%2029%20Toleransedoser%20og%20anbefalte%20dosegrenser%20til%20risikoorganer%20ved%20str%C3%A5lebehandling%20av%20sentralnervesystemet%20.pdf

Burman, P., Casar-Borota, O., Perez-Rivas, L. G., & Dekkers, O. M. (2023). Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. The Journal of Clinical Endocrinology & Metabolism, 108(7), 1585-1601.

Burman, P., Mattsson, A. F., Johannsson, G., Höybye, C., Holmer, H., Dahlqvist, P., Berinder, K., Engström, B. E., ... Karlsson, F. A. (2013). Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism, 98(4), 1466-75.

Daly, A. F., & Beckers, A. (2015). Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinology and Metabolism Clinics of North America, 44(1), 19-25.

Dekkers, O. M., Pereira, A. M., & Romijn, J. A. (2008). Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism, 93(10), 3717-26.

Ding, D., Starke, R. M., & Sheehan, J. P. (2014). Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. Journal of Neuro-Oncology, 117(3), 445-57.

Eaton, D. J., Lee, J., Patel, R., Millin, A. E., Paddick, I., & Walker, C. (2018). Stereotactic radiosurgery for benign brain tumors: Results of multicenter benchmark planning studies. Practical Radiation Oncology, 8(5), e295-e304.

Erridge, S. C., Conkey, D. S., Stockton, D., Strachan, M. W., Statham, P. F., Whittle, I. R., Grant, R., Kerr, G. R., & Gregor, A. (2009). Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiotherapy and Oncology, 93(3), 597-601.

Freda, P. U., Beckers, A. M., Katznelson, L., Molitch, M. E., Montori, V. M., Post, K. D., & Vance, M. L. (2011). Pituitary incidentaloma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96(4), 894-904.

Freda, P. U., Wardlaw, S. L., & Post, K. D. (1996). Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. Journal of Clinical Endocrinology and Metabolism, 81(10), 3455-9.

Frieze, T. W., Mong, D. P., & Koops, M. K. (2002). "Hook effect" in prolactinomas: case report and review of literature. Endocrine Practice, 8(4), 296-303.

Gillett, D., Senanayake, R., MacFarlane, J., van der Meulen, M., Koulouri, O., Powlson, A. S., Crawford, R., Gillett, B., ... Gurnell, M. (2022). Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. EJNMMI research, 12(1), 26.

Gnanalingham, K. K., Bhattacharjee, S., Pennington, R., Ng, J., & Mendoza, N. (2005). The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. Journal of Neurology, Neurosurgery and Psychiatry, 76(3), 415-9.

Gravdahl, G. B., Tronvik, E. A., Fougner, S. L., & Solheim, O. (2016). Pituitary Adenoma and Non-acute Headache: Is There an Association, and Does Treatment Help?. World Neurosurgery, 92, 284-291.

Helse- og omsorgsdepartementet (2006). Nasjonal strategi for kreftområdet 2006-2009 Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/

Helse- og omsorgsdepartementet (2006). Nasjonal helseplan (2007–2010) (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf

Helse- og omsorgsdepartementet (2013). Sammen - mot kreft: nasjonal kreftstrategi 2013-2017 Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/sammen---mot-kreft/id728818/

Helse- og omsorgsdepartementet (2018). Leve med kreft: nasjonal kreftstrategi (2018–2022) Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/

Hurel, S. J., Thompson, C. J., Watson, M. J., Harris, M. M., Baylis, P. H., & Kendall-Taylor, P. (1996). The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis. Clinical Endocrinology, 44(2), 141-6.

Jørgensen, A. P., Tazmini, K., red. (8. april 2020). Nasjonal veileder i endokrinologi. [nettdokument]. Oslo: Norsk Endokrinologisk Forening. Hentet 8. juni 2020 fra https://www.endokrinologi.no/

Kaltsas, G. A., Evanson, J., Chrisoulidou, A., & Grossman, A. B. (2008). The diagnosis and management of parasellar tumours of the pituitary. Endocrine-Related Cancer, 15(4), 885-903.

Kong, D. S., Lee, J. I., Lim, D. H., Kim, K. W., Shin, H. J., Nam, D. H., Park, K., & Kim, J. H. (2007). The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer, 110(4), 854-60.

Kontogeorgos, G. (2005). Classification and pathology of pituitary tumors. Endocrine, 28(1), 27-35.

Landberg, T., Chavaudra, J., Dobbs, J., Gerard, J. P., Hanks, G., Horiot, J. C., Johansson, K. A., Möller, T., ... Svensson, H. (1999). Report 62: prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU report 50). Journal of the ICRU, os32(1)

Landberg, T., Chavaudra, J., Dobbs, J., Hanks, G., Johansson, K., Möller, T., & Purdy, J. (1993). Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Journal of the ICRU, os26(1)

Levernes, S. (2012). Volum og doser i ekstern stråleterapi: definisjoner og anbefalinger (StrålevernRapport 2012:9). Østerås: Statens strålevern. Hentet fra https://dsa.no/medisinsk-stralebruk/kvist/_/attachment/download/bee8860b-36d1-42e7-8d64-f5ad4fcef2e8:8ebb86decddc2818ec31e4999d26cdf7aec14ac2/StralevernRapport_09-2012.pdf

Levernes, S. (2019). Faglige anbefalinger for nomenklatur for volumer i stråleterapi (Teknisk dokument 14). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/download/9d2a42a5-241e-4299-86cf-6b02a0abf3b9:2400dff7cb71f4bff583473d690fcb79650dd59e/TekniskDokument14_rev2020.pdf

Loeffler, J. S., & Shih, H. A. (2011). Radiation therapy in the management of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 96(7), 1992-2003.

Magge, R. (2019-2022). Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas (TMZ-Cap) [pågående studie]. (NCT03930771). Hentet fra https://www.clinicaltrials.gov/study/NCT03930771

Marienhagen, K., Djupvik, L. H., Danielsen, T. (2020). Faglige anbefalinger for inntegning av risikoorganer i CNS (Teknisk dokument 16). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/download/401a60b3-b7db-4c4a-b741-da0a70c43b20:f0c3325a0ec4a43b2335cf17df266e4e7c34408c/Teknisk%20dokument16_rev.pdf

Mathieu, D., Kotecha, R., Sahgal, A., De Salles, A., Fariselli, L., Pollock, B. E., Levivier, M., Ma, L., ... Sheehan, J. P. (2022). Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations. Journal of Neuro-Oncology, 136(3), 801-812.

Miermeister, C. P., Petersenn, S., Buchfelder, M., Fahlbusch, R., Lüdecke, D. K., Hölsken, A., Bergmann, M., Knappe, H. U., ... Buslei, R. (2015). Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications. Acta neuropathologica communications, 3, 50.

Minniti, G., Clarke, E., Scaringi, C., & Enrici, R. M. (2016). Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 21(4), 370-8.

Minniti, G., Flickinger, J., Tolu, B., & Paolini, S. (2018). Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary, 21(2), 154-161.

Minniti, G., Gilbert, D. C., & Brada, M. (2009). Modern techniques for pituitary radiotherapy. Reviews in Endocrine & Metabolic Disorders, 10(2), 135-44.

Minniti, G., Osti, M. F., & Niyazi, M. (2016). Target delineation and optimal radiosurgical dose for pituitary tumors. Radiation Oncology (London, England), 11(1), 135.

Molitch, M. E. (2008). Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas. Endocrinology and Metabolism Clinics of North America, 37(1), 151-171.

Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96(6), 1587-609.

Müller, H. L., Merchant, T. E., Puget, S., & Martinez-Barbera, J. P. (2017). New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nature Reviews: Endocrinology, 13(5), 299-312.

Murad, M. H., Fernández-Balsells, M. M., Barwise, A., Gallegos-Orozco, J. F., Paul, A., Lane, M. A., Lampropulos, J. F., Natividad, I., ... Montori, V. M. (2010). Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clinical Endocrinology, 73(6), 777-91.

Raappana, A., Koivukangas, J., Ebeling, T., & Pirilä, T. (2010). Incidence of pituitary adenomas in Northern Finland in 1992-2007. Journal of Clinical Endocrinology and Metabolism, 95(9), 4268-75.

Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., & Dekkers, O. M. (2018). European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology of the European Federation of Endocrine Societies, 178(1), G1-G24.

Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. (2007). Journal of the ICRU, 7(7)

Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT). (2010). Journal of the ICRU, 10(1)

Sheehan, J. P., Pouratian, N., Steiner, L., Laws, E. R., & Vance, M. L. (2011). Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. Journal of Neuro-Oncology, 114(2), 303-9.

Sheehan, J. P., Starke, R. M., Mathieu, D., Young, B., Sneed, P. K., Chiang, V. L., Lee, J. Y., Kano, H., ... Lunsford, L. D. (2013). Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. Journal of Neuro-Oncology, 119(2), 446-56.

Tjörnstrand, A., Casar-Borota, O., Heurling, K., Schöll, M., Gjertsson, P., Ragnarsson, O., & Filipsson Nyström, H. (2021). Pre- and postoperative (68) Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours. Clinical Endocrinology, 94(6), 956-967.

Tjörnstrand, A., Gunnarsson, K., Evert, M., Holmberg, E., Ragnarsson, O., Rosén, T., & Filipsson Nyström, H. (2014). The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. European Journal of Endocrinology of the European Federation of Endocrine Societies, 171(4), 519-26.

van Westrhenen, A., Muskens, I. S., Verhoeff, J. J. C., Smith, T. R. S., & Broekman, M. L. D. (2017). Ischemic stroke after radiation therapy for pituitary adenomas: a systematic review. Journal of Neuro-Oncology, 135(1), 1-11.

Watanabe, G., Choi, S. Y., & Adamson, D. C. (2022). Pituitary Incidentalomas in the United States: A National Database Estimate. World Neurosurgery, 158, e843-e855.

WHO Classification of Tumours Editorial Board (2022). Endocrine and neuroendocrine tumours (5 utg.) Lyon: IARC Press.